Myocardial Work Efficiency, A Novel Measure of Myocardial Dysfunction, Is Reduced in COVID-19 Patients and Associated With In-Hospital Mortality

Anum S. Minhas \textsuperscript{1†}, Nisha A. Gilotra \textsuperscript{1†}, Erin Goerlich \textsuperscript{1}, Thomas Metkus \textsuperscript{1}, Brian T. Garibaldi \textsuperscript{2}, Garima Sharma \textsuperscript{1}, Nicole Bavaro \textsuperscript{1}, Susan Phillip \textsuperscript{1}, Erin D. Michos \textsuperscript{1} and Allison G. Hays \textsuperscript{1*}

\textsuperscript{1} Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States, \textsuperscript{2} Division of Pulmonary and Critical Care Medicine, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States

Background: Although troponin elevation is common in COVID-19, the extent of myocardial dysfunction and its contributors to dysfunction are less well-characterized. We aimed to determine the prevalence of subclinical myocardial dysfunction and its association with mortality using speckle tracking echocardiography (STE), specifically global longitudinal strain (GLS) and myocardial work efficiency (MWE). We also tested the hypothesis that reduced myocardial function was associated with increased systemic inflammation in COVID-19.

Methods and Results: We conducted a retrospective study of hospitalized COVID-19 patients undergoing echocardiography (\(n = 136\)), of whom 83 and 75 had GLS (abnormal >−16\%) and MWE (abnormal <95\%) assessed, respectively. We performed adjusted logistic regression to examine associations of GLS and MWE with in-hospital mortality. Patients were mean 62 ± 14 years old (58\% men). While 81\% had normal left ventricular ejection fraction (LVEF), prevalence of myocardial dysfunction was high by STE; [39/83 (47\%) had abnormal GLS; 59/75 (79\%) had abnormal MWE]. Higher MWE was associated with lower in-hospital mortality in unadjusted [OR 0.92 (95\% CI 0.85–0.99); \(p = 0.048\)] and adjusted models [aOR 0.87 (95\% CI 0.78–0.97); \(p = 0.009\)]. In addition, increased systemic inflammation measured by interleukin-6 level was associated with reduced MWE.

Conclusions: Subclinical myocardial dysfunction is common in COVID-19 patients with clinical echocardiograms, even in those with normal LVEF. Reduced MWE is associated with higher interleukin-6 levels and increased in-hospital mortality. Non-invasive STE represents a readily available method to rapidly evaluate myocardial dysfunction in COVID-19 patients and can play an important role in risk stratification.

Keywords: echo, strain, COVID-19, non-invasive, ultrasound diagnosis
INTRODUCTION

COVID-19, the disease caused by the novel coronavirus SARS-CoV2, carries high acute cardiovascular morbidity and mortality (1, 2). The mechanisms for cardiac injury are not fully understood, with hypotheses ranging from systemic inflammation due to cytokine release syndrome, angiotensin converting enzyme-2 mediated direct viral myocardial toxicity, autoimmune myocarditis, and sympathetic stress response (1, 3). Over 25% of hospitalized COVID-19 patients have acute cardiac injury as detected by elevated cardiac troponin, associated with greater in-hospital mortality (1, 3, 4). However, troponin alone has limited specificity and sensitivity in myocarditis and can also rise in acute respiratory distress syndrome (ARDS), another recognized complication of COVID-19 (5–7). Additionally, although multiple inflammatory pathways, such as interleukin-6 (IL-6), are implicated in myocardial injury in COVID-19, their effect on indices of cardiac function is unknown and a better understanding of the degree and determinants of myocardial function may improve risk stratification and lead to new therapeutic approaches (8–10).

Studies examining the degree of myocardial dysfunction in COVID-19 are limited, and assessment with cardiac imaging has been challenging due to exposure concerns to echocardiography staff. Thus, it is likely that the true prevalence of cardiac dysfunction is underreported (11). Speckle tracking echocardiography (STE) can rapidly quantify myocardial dysfunction (e.g., using global longitudinal strain [GLS]) with increased sensitivity compared with standard echocardiographic measures (12–14). More recently, a novel technique to measure LV function based on STE, global myocardial work (MW), was developed (15, 16). The advantage of MW [assessed by myocardial work index (MWI) and myocardial work efficiency (MWE)], is that it provides a more load independent measure of LV function by accounting for afterload; MW is also highly reproducible and adds incremental value to GLS in predicting adverse events (17).

Given the high mortality and severity of complications with COVID-19, we conducted a clinical cardiac imaging study in hospitalized COVID-19 patients with echocardiograms performed with the following aims: (1) to determine the prevalence and extent of myocardial dysfunction using STE (GLS and MWE), (2) to examine the association of myocardial dysfunction with in-hospital mortality, and (3) to investigate clinical and inflammatory biomarker risk factors associated with worsened subclinical myocardial dysfunction.

METHODS

Study Design

This retrospective, single-center cohort study included 136 consecutive patients with confirmed COVID-19 who were hospitalized at Johns Hopkins Hospital and underwent clinically indicated transthoracic echocardiogram between March 25, 2020 and May 19, 2020, with follow-up completed by June 22, 2020. All echocardiograms were ordered by the patient’s clinical care team. The study was approved by the Johns Hopkins Institutional Review Board and informed consent was waived per IRB guidelines.

Clinical Data

Patient characteristics, including demographics, medical history, clinical presentation, laboratory testing, and clinical outcomes were extracted from the electronic medical record. Initial values after admission for the following serum biomarkers were collected: cardiac troponin I, IL-6, C-reactive protein (CRP), ferritin, fibrinogen, and d-dimer. In-hospital all-cause mortality during index hospitalization was ascertained from electronic medical records through the end of follow-up. Two separate investigators independently reviewed the data.

Transthoracic Echocardiography

Conventional 2D Echocardiographic Analysis

Bedside transthoracic echocardiographic (TTE) examinations were performed by experienced sonographers using VividTM E95 ultrasound system (GE Vingmed Ultrasound; Horten, Norway). Both standard 2D and Doppler echocardiography were acquired. Measurements including LV, right ventricular (RV) parameters and diastology were performed by a dedicated research sonographer based on the American Society of Echocardiography (ASE) guidelines (18, 19). To limit exposure to patients and staff, measurements that were not essential, including STE analyses, were performed offline, removed from the patient’s room, and limited studies were performed according to COVID-19 specific imaging guidelines (20).

Speckle Tracking Echocardiography Analysis

STE analyses were conducted according to ASE recommendations in a subset of TTEs that were (1) deemed to be of fair quality or greater for subendocardial image visualization by two independent readers and (2) in a patient free of atrial or ventricular arrhythmias at the time of exam (n = 83) (18). Two-dimensional images from the apical four-chamber, two-chamber, and long-axis views were acquired with frame rates between 50 and 80 frames/s to enable GLS. GLS was quantified using semiautomated analysis software (EchoPAC version 202; GE Vingmed Ultrasound). The automated algorithm traces and tracks the LV myocardium, with manual adjustments made when appropriate, and the software calculates GLS from the weighted average of the peak systolic longitudinal strain of all segments using the 17 segment model. GLS is quantified as a negative number with cutoff as −18%, and more negative as normal for this system, but based on prior literature supporting use of a cutoff of −16% as the threshold.
for normal, analyses were conducted with > −16% as the
cutoff for normal (21–25). Tracking quality was assessed by
the operator and over-ridden in segments with two or fewer
rejected regions where the operator deemed tracking quality
to be acceptable. Images were analyzed by two independent
observers blinded to clinical data on a dedicated offline research
workstation. Intraobserver and interobserver variability of
STE measures, specifically MWE, were assessed by intra-
class correlation coefficient (individual ICC of 0.994 and average ICC
of 0.997 for intraobserver and 0.992 and 0.995 for interobserver,
respectively), and Bland-Altman analysis (all differences in
measurements within ±1 SD). The time between intraobserver
measurements was 1 day.

Myocardial Work
Myocardial work (MW) was determined from non-invasive LV
pressure-strain analysis, which has previously been described
and validated (26, 27). MW is calculated as the area of
the pressure-strain loop, similar in concept to deriving LV
stroke work using pressure volume loops invasively. In this
technique, pressures are assessed using brachial systolic pressure
and valvular event timing and strain measured with STE (15,
16). MW indices were calculated with the same software as
above to evaluate LV performance by incorporating afterload
determination using blood pressure; this provides a more load-
independent measure compared with GLS (27). Blood pressure
was measured by sphygmomanometry at the time of the

FIGURE 1 | Global longitudinal strain and myocardial work efficiency measurement in patients with COVID-19. Global longitudinal strain and myocardial work index
bull’s eye mapping for two patients with COVID-19. (A) representative patient with relatively normal strain and myocardial work; (B) representative patient with severely
reduced global longitudinal strain (apical predominant), myocardial work index, and work efficiency. ANT, anterior; ANT SEPT, anteroseptal; APLAX, apical long axis;
AVC, aortic valve closure; CH, chamber; GS, global strain; HR, heart rate; INF, inferior; LAT, lateral; POST, posterior; PSD, peak systolic dispersion; SEPT, septal; SL,
strain length.
performed to evaluate inflammatory markers (divided into tertiles given non-normal distribution) as predictors of MWE. Values within each tertile are included in the supplement. These markers included IL6, troponin, ferritin, C-reactive protein (CRP), d-dimer, and fibrinogen. Missing data were considered to occur at random, and patients with missing inflammatory data were not included in this analysis.

RESULTS

Clinical Characteristics of Patients Undergoing Echocardiogram

Median time of symptom duration prior to admission was 6 days (3–8 days). Median time to echocardiogram after admission was 4 days (2–8 days) and median overall time of admission was 16.5 days (9–31 days).

Clinical characteristics of hospitalized patients with COVID-19 who had echocardiogram performed are shown in Table 1 (n = 136). The mean age was 62 years, 79 (58%) were men and 63 (47%) African American. Approximately 63% of patients required mechanical ventilation, 57% were diagnosed with ARDS and 53% had shock (septic, distributive, cardiogenic or otherwise) (Table 1).

The cohort of patients with echocardiograms performed was comparable to the subset of patients with GLS and MWE measured (Table 1). The majority of patients (81%) undergoing echocardiogram had normal LV systolic function by LVEF measurement. Follow-up (discharged as alive or deceased) was complete for 131/136 patients, while 5/136 (3.7%) were administratively censored (still admitted at the time of analysis).

Clinical and Echocardiographic Characteristics for Patients With Global Longitudinal Strain Assessed

Among the patients with GLS performed (n = 83), 44 patients had normal GLS and 39 (47%) had abnormal GLS (Table 1). There were no significant differences in age, sex, race, or history of hypertension or CAD between patients with and without abnormal GLS. There was higher prevalence of diabetes mellitus in the abnormal compared with normal GLS group (51 vs. 27%, p = 0.025). Body mass index (BMI) was significantly higher in patients with abnormal compared with normal GLS (median 31.4 vs. 27.8 kg/m², p = 0.017). Patients with abnormal GLS had lower LVEF (55 vs. 62%, p < 0.001), and lower TAPSE (1.7 vs. 2.0 cm, p = 0.005) when compared with those with normal GLS.

Among the inflammatory markers, interleukin-6 was higher among patients with abnormal GLS [median 164 (69–815)] compared with normal GLS [median 86 (32–167)], p = 0.034. All other inflammatory markers were not significantly different (Table 1). The value ranges of each inflammatory marker per tertile are presented in Supplementary Table 1.

Clinical and Echocardiographic Characteristics for Patients With Myocardial Work Efficiency Assessed

Among the subgroup of patients with myocardial work imaging performed (N = 75), abnormal MWE (defined as <95%) was...
### TABLE 1 | Comparison of clinical characteristics and echocardiographic parameters in the cohort of hospitalized patients with COVID-19 and subgroups with normal vs. abnormal global longitudinal strain (GLS) and myocardial work efficiency (MWE).

| Variables             | Overall cohort  | Normal GLS N = 44 | Abnormal GLS N = 39 | p-value | Normal MWE N = 16 | Abnormal MWE N = 59 | p-value |
|-----------------------|-----------------|-------------------|---------------------|---------|-------------------|---------------------|---------|
| **Laboratory measures** |                 |                   |                     |         |                   |                     |         |
| White                 | 34 (25%)        | 10 (23%)          | 5 (13%)             | 0.347   | 3 (19%)           | 12 (21%)            | 0.082   |
| African American      | 63 (47%)        | 20 (45%)          | 23 (61%)            | 0.140   | 5 (31%)           | 33 (57%)            | 0.077   |
| Other                 | 37 (27%)        | 14 (32%)          | 10 (26%)            | 0.001   | 8 (50%)           | 13 (22%)            | 0.049   |
| Body mass index, kg/m² | 30.0 (26.4–35.8) | 27.8 (25.6–31.3) | 31.4 (26.5–38.4)   | 0.017   | 27.7 (25.7–31.8) | 28.7 (25.7–34.5)   | 0.544   |
| **Comorbidities**     |                 |                   |                     |         |                   |                     |         |
| Hypertension          | 97 (72%)        | 29 (66%)          | 30 (77%)            | 0.269   | 7 (44%)           | 46 (78%)            | 0.008   |
| Diabetes mellitus     | 55 (41%)        | 12 (27%)          | 20 (51%)            | 0.025   | 1 (6%)            | 29 (49%)            | 0.020   |
| Coronary artery disease| 20 (15%)     | 4 (9%)            | 8 (21%)             | 0.140   | 0 (0%)            | 10 (17%)            | 0.077   |
| Heart failure         | 20 (15%)        | 2 (5%)            | 12 (31%)            | 0.001   | 0 (0%)            | 12 (20%)            | 0.049   |
| **Clinical presentation** |             |                   |                     |         |                   |                     |         |
| Heart rate, beats per min | 99 ± 20      | 97 ± 17           | 103 ± 21            | 0.151   | 95 ± 18           | 100 ± 20            | 0.392   |
| Systolic blood pressure, mmHg | 129 ± 25   | 129 ± 24          | 134 ± 24            | 0.368   | 126 ± 27          | 132 ± 23            | 0.343   |
| Diastolic blood pressure, mmHg | 71 ± 16   | 71 ± 16            | 74 ± 15             | 0.389   | 74 ± 16           | 71 ± 16             | 0.546   |
| **Echocardiographic parameters** |               |                   |                     |         |                   |                     |         |
| LA volume, ml         | 44 (35–71)      | 41 (29–45)        | 48 (39–95)          | 0.046   | 39.5 (28–42)     | 47 (39–55)          | 0.222   |
| LVEDD, cm             | 4.2 (3.7–4.8)   | 4.1 (3.8–4.6)     | 4.3 (3.4–4.9)       | 0.378   | 4.4 (3.8–4.9)    | 4.1 (3.5–4.7)       | 0.276   |
| LVEF, %               | 62 (52–62)      | 62 (57–64)        | 55 (40–62)          | <0.001  | 62 (62–64)       | 57 (50–62)          | 0.011   |
| Normal LVEF (>50%)    | 109 (81%)       | 43 (64%)          | 24 (36%)            | <0.001  | 16 (100%)        | 45 (74%)            | 0.031   |
| RVEDD, cm             | 3.6 ± 0.7       | 3.4 ± 0.6         | 3.6 ± 0.7           | 0.224   | 3.4 ± 0.7        | 3.6 ± 0.6           | 0.225   |
| Normal RV function    | 63 (81%)        | 22 (85%)          | 18 (72%)            | 0.274   | 12 (92%)         | 24 (73%)            | 0.147   |
| TAPSE, cm             | 1.8 ± 0.4       | 2.0 ± 0.4         | 1.7 ± 0.4           | 0.005   | 2.1 ± 0.3        | 1.8 ± 0.4           | 0.003   |
| RVSP, mmHg            | 37 (30–50)      | 37 (29–48)        | 34 (32–53)          | 0.742   | 31 (30–33)       | 37 (29–49)          | 0.288   |
| Mean PAP, mmHg        | 34 ± 12         | 35 ± 9            | 34 ± 11             | 0.754   | 27 ± 12          | 35 ± 9              | 0.067   |
| Peak TR gradient, mmHg| 31 (25–42)      | 32 (25–42)        | 31 (25–40)          | 0.899   | 29 (25–38)       | 31 (24–43)          | 0.032   |
| PCWP, mmHg            | 14 (10–18)      | 13 (9–17)         | 12 (9–16)           | 0.820   | 12 (10–16)       | 15 (12–21)          | 0.422   |
| E/E                   | 15 (10–13)      | 15 (10–12)        | 13 (9–13)           | 0.665   | 9 (7–11)         | 9 (7–13)            | 0.561   |
| GLS, %                | −16.1 ± 4.3     | −19.2 ± 2.4       | −12.6 ± 3.0         | <0.001  | −19.7 ± 3.1      | −15.5 ± 4.1         | <0.001  |
| MVI, mmHg%            | 1,412 ± 425     | 1,579 ± 362       | 1,227 ± 417         | <0.001  | 1,723 ± 399      | 1,331 ± 396         | <0.001  |
| MWE, %                | 92 (87–94)      | 94 (91–95)        | 89 (82–92)          | <0.001  | 96 (95–96)       | 91 (86–93)          | <0.001  |

Categorical variables are presented as number (%) and continuous variables are presented as mean ± standard deviation or median (interquartile range). CRP, C-reactive protein; Pro-BNP, N-terminal pro-hormone B-type natriuretic peptide; ARDS, acute respiratory distress syndrome; DVT, deep venous thrombosis; PE, pulmonary embolism; LA, left atrium; LVEDD, left ventricular end diastolic diameter; LVEF, left ventricular ejection fraction; GLS, global longitudinal strain; RVEDD, right ventricular end diastolic diameter; TAPSE, tricuspid annular plane systolic excursion; RVSP, right ventricular systolic pressure; PAP, pulmonary artery pressure; TR, tricuspid regurgitation; GLS, global longitudinal strain; MVI, myocardial work index; MWE, myocardial work efficiency.

The bold values represent significant p-values, with significant defined as <0.05.
present in the majority (59/75, 79%). There were no significant differences in demographics or clinical presentation between patients with normal vs. abnormal MWE (Table 1). A history of hypertension was more common among patients with abnormal MWE compared with normal MWE (78 vs. 44%, \( p = 0.008 \)), as was a prior history of diabetes (29 vs. 1%, \( p = 0.002 \)). Patients with abnormal MWE compared with those with normal MWE had lower LVEF (57 vs. 62%, \( p = 0.011 \)), and lower TAPSE (1.8 vs. 2.1 cm, \( p = 0.003 \)).

Among patients with normal LVEF \( (n = 67) \), a high percentage had evidence of subclinical myocardial dysfunction using STE: 36% had abnormal GLS (GLS >−16%) and 74% had abnormal MWE (MWE <95%) (Figure 2).

### Association of Clinical Characteristics and Speckle Tracking Echocardiography Measurements With Mortality

During hospital admission, 25 (19%) of patients experienced in-hospital death. No clinical characteristics were independently associated with mortality in univariate analysis. MWE was the only echocardiographic parameter independently associated with mortality [unadjusted OR 0.92 (95% CI 0.85–0.99), \( p = 0.048 \)]. In adjusted Models 1–2, MWE remained associated with mortality, with the strongest association in Model 2 [OR 0.87 (95% CI 0.78–0.97), \( p = 0.009 \)] (Table 2), suggesting that a 1% increase in MWE was associated with 13% lower odds of death.

Additional subgroup analyses performed to confirm the relationship of MWE and mortality showed similar findings. Among patients with normal LVEF, higher MWE was again independently inversely associated with death [unadjusted OR 0.89 (95% CI 0.78–1.00), \( p = 0.050 \)]. MWE was also associated with in-hospital death after adjusting for age and sex \( [\text{aOR 0.85 (95\% CI 0.74–0.99, } p = 0.038] \). GLS was not associated with death in adjusted or unadjusted analysis. No echocardiographic parameter (LVEF, GLS, or MWE) was associated with mortality in subgroup analyses of patients with and without ARDS (Supplementary Table 2).

As MWE was the only echocardiographic parameter associated with mortality, we then evaluated systemic inflammatory markers as predictors of abnormal MWE in a subset of patients with available inflammatory marker data. We observed that MWE was 2.04% lower per higher tertile of IL-6 level \( (p = 0.021) \), indicating that greater degree of inflammation reflected by IL-6 levels were associated with worse myocardial function as measured using MWE. All other inflammatory markers tested were associated with no difference in MWE (Figure 3).

### DISCUSSION

We report that subclinical cardiac dysfunction measured by GLS and MWE on STE is common in hospitalized COVID-19 patients with clinically indicated echocardiograms performed. To our knowledge, this is one of the first reports characterizing novel echocardiographic indices of myocardial dysfunction (GLS and the newer imaging parameter MWE) in hospitalized patients with COVID-19. We report several unique findings in our population: (1) Subclinical myocardial dysfunction is prevalent among COVID-19 patients even in the setting of normal LVEF, especially in those with traditional cardiovascular risk factors, (2) lower, more abnormal MWE, which is a sensitive measure of load independent myocardial dysfunction, is associated with greater in-hospital mortality, and (3) higher level of the inflammatory marker, IL-6, is predictive of lower MWE. Importantly, the finding of the association of MWE with mortality held true even after analyzing patients with normal LVEF, suggesting the prognostic benefit of MWE over LVEF and supporting use of MWE in addition to LVEF for hospitalized patients with COVID-19.

### Speckle Tracking Echocardiography for the Detection of Subclinical Myocardial Dysfunction in COVID-19 Patients

Both GLS and MWE are sensitive measures of LV function and cardiac injury, and the current study is among the first to characterize these indices in the setting of acute COVID-19 (37, 38). Compared with LVEF, GLS improves risk stratification, enhances disease classification, and may guide the treatment approach in asymptomatic patients with subclinical LV dysfunction (14, 38). Both GLS and MWE measurements are validated, reproducible, and do not require additional imaging beyond standard TTE, reducing potential additional provider exposure during image acquisition. Prior studies have consistently demonstrated reduced GLS despite a preserved LVEF among patients at increased risk for cardiac injury and dysfunction (39). MWE is a newer load-independent measure that permits both global and regional ventricular mechanics to be analyzed through the relationship between myocardial contractility and LV pressure (15). A previous study showed that non-invasive indices of myocardial work are more sensitive than GLS for the detection of significant CAD in patients with normal regional wall motion and preserved LVEF (17). The present study supports these prior findings, as abnormal MWE was even more prevalent than abnormal GLS (79 vs. 46% of patients). Additionally, patients with abnormal STE indices were more likely to have cardiovascular risk factors than those with normal indices, even among those with normal LVEF.

### Myocardial Work Efficiency and Mortality

While recent data has suggested high incidence of acute cardiac injury by troponin levels in COVID-19, investigations into the extent and implications of myocardial dysfunction on adverse outcomes such as death are limited (1, 7, 13, 40–42). In the present study, in a cohort with comparable in-hospital mortality to prior studies in COVID-19, we demonstrate the ability of MWE to predict mortality while GLS and LVEF did not. Prior studies suggest that the amount of myocardial work is related to uptake of fluoro-deoxy-glucose at myocardial positron emission tomography scan, suggesting a relationship between myocardial work efficiency and metabolism (27). It is possible that impaired
MWE may be related to derangements in myocardial metabolism that can occur in the setting of increased systemic inflammation.

Based on these findings, it is possible that STE measures of subclinical LV dysfunction may provide incremental value to standard echo measures in patients with COVID-19. Given the acuity of presentation and cardiovascular complications of COVID-19, a better understanding of the extent of myocardial injury and dysfunction early in the disease course may help triage at risk patients and implement early interventions aimed at reducing mortality.

**Systemic Inflammation and Cardiac Dysfunction**

Although recent studies have aimed to describe pathophysiologic processes leading to RV strain and dilation in acute COVID-19 (43, 44), LV dysfunction and particularly subclinical dysfunction on STE, have not been as well-investigated. Studies suggest that increased systemic inflammation and impaired immune function may play a role (6, 7). Potential causes of myocardial dysfunction include myocarditis, ischemic injury (caused by microvascular dysfunction or epicardial CAD), stress cardiomyopathy or...
cytokine release syndrome (45). Autopsy studies of severe COVID-19 disease suggest there can also be direct viral-induced injury of multiple organs, including the heart (46). However, the relative contribution and determinants of myocardial dysfunction have not been well-characterized, partially due to limited ability to obtain widespread cardiac testing in these patients. Given these limitations, the true prevalence of cardiac dysfunction has likely been underreported thus far, and is mainly limited to case reports (6, 7).

In our study, patients underwent echocardiography at a median 4 days after hospital admission and 6 days of symptom onset, suggesting that impaired GLS and MWE occur early in COVID-19 during the systemic inflammatory response, and cannot entirely be explained by a more chronic myocardial process such as fibrosis. In addition, COVID-19 patients with LV dysfunction on STE had more obesity, which is a pro-inflammatory state that initiates oxidative stress and adversely affects immune function, leading to cardiac injury (40, 47, 48). Finally, although inflammatory pathways have been implicated in myocardial injury related to COVID-19, their effect on important indices of cardiac function has not been well-characterized. In the present study, we show that subclinical myocardial dysfunction is related to the degree of systemic inflammation measured by IL-6. IL-6 has previously been shown to act as a key cytokine in producing downstream effects resulting in organ damage, including reduced myocardial contractility (49–51).

Additionally, IL-6 levels in the setting of COVID-19 have been reported to be elevated in several studies and have been shown to correlate with mortality (52–54). Our study, along with these prior studies, supports a potential role of IL-6 and heightened inflammation in mediating myocardial dysfunction, thereby increasing risk of death. Of note, we did not find a similar relationship with troponin and myocardial dysfunction, likely related to the primarily normal-range troponin values for the majority of patients.

By characterizing subclinical myocardial dysfunction using STE, the present study provides incremental knowledge, linking increased systemic inflammation (by IL-6 levels) to the pathophysiology of myocardial injury and dysfunction in COVID-19.

Limitations
The main limitation of this study is the relatively small sample size and retrospective cohort study design. Larger prospective studies are needed to further explore these novel echocardiographic parameters (GLS and MWE) with regard to cardiovascular mortality and other clinically meaningful outcomes in COVID-19 disease. Also, not all hospitalized

FIGURE 3 | Association of myocardial work efficiency with inflammatory markers. Inflammatory markers are analyzed by tertile of each marker given non-normal distribution.
COVID-19 patients underwent echocardiogram and STE, which could result in selection bias and inability to detect true prevalence of abnormal GLS or MWE among COVID-19 patients. Lastly, a minority of patients with GLS and MWE performed did not have all inflammatory markers tested clinically, thus limiting the analyses.

CONCLUSIONS

In summary, sensitive indices of LV dysfunction, GLS and MWE, measured with STE are abnormal in a substantial portion of hospitalized COVID-19 patients who underwent echocardiograms, even in those with normal LVEF. Impaired MWE is independently associated with in-hospital mortality in COVID-19 patients. Higher IL-6 levels are associated with reduced MWE, providing a possible pathophysiologic link between increased inflammation and adverse outcomes in COVID-19 patients. Higher IL-6 levels are associated with reduced MWE, providing a possible pathophysiologic link between increased inflammation and adverse outcomes in COVID-19. Based on these findings, it is possible that STE measures of subclinical LV dysfunction may provide incremental value to standard echocardiographic measures in patients with COVID-19. Given the acuity of presentation and cardiovascular complications of COVID-19, a better understanding of the extent of myocardial injury and dysfunction early in the disease course may help triage at risk patients and implement early interventions aimed at reducing mortality. Further longitudinal studies are needed to investigate persistence of impaired cardiac function in the setting of COVID-19.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Johns Hopkins IRB. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

AUTHOR CONTRIBUTIONS

AM, NG, EG, and AH drafted the manuscript. BG, TM, GS, SP, and NB edited the manuscript. AM, NG, EG, and NB collected the data. AM analyzed the data and performed statistical analysis. All authors contributed to the article and approved the submitted version.

FUNDING

AM was supported by the National Heart, Lung, and Blood Institute training Grant T32HL007024. AH was supported by the National Heart, Lung, and Blood Institute Grant 1R01HL147660. This study received device and funding support from GE Healthcare. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcvm.2021.667721/full#supplementary-material

REFERENCES

1. Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. (2020) 5:811–8. doi: 10.1001/jamacardiol.2020.1017
2. Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. (2020) 5:802–10. doi: 10.1001/jamacardiolo.2020.0950
3. Hoffmann M, Kleine-Weber H, Schroder S, Kruger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. (2020) 181:271–80.e8. doi: 10.1016/j.cell.2020.02.052
4. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5,700 patients hospitalized with COVID-19 in the New York City area. JAMA. (2020) 323:2052–9. doi: 10.1001/jama.2020.26775
5. Gilnota NA, Minkove N, Bennett MK, Tefrdor RJ, Steenbergen C, Judge DP, et al. Lack of relationship between serum cardiac troponin I level and giant cell myocarditis diagnosis and outcomes. J Cardiac Fail. (2016) 22:583–5. doi: 10.1016/j.cardfail.2015.12.022
6. Hu H, Ma F, Wei X, Fang Y. Coronavirus fulminant myocarditis treated with glucocorticoid and human immunoglobulin. Eur Heart J. (2020) 4:260. doi: 10.1093/eurheartj/ehaa190
7. Inciardi RM, Lupi L, Zaccone G, Italia L, Raffo M, Tomasoni D, et al. Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19). JAMA Cardiol. (2020) 5:819–24. doi: 10.1001/jamacardio.2020.1096
8. Zeng F, Huang Y, Guo Y, Yin M, Chen X, Xiao L, et al. Association of inflammatory markers with the severity of COVID-19: A meta-analysis. Int J Infect Dis. (2020) 96:467–74. doi: 10.1016/j.ijid.2020.05.055
9. Rali AS, Ranka S, Shah Z, Sauer AJ. Mechanisms of myocardial injury in coronavirus disease 2019. Card Fail Rev. (2020) 6:e15. doi: 10.15442/cfr.2020.10
10. Chen C, Zhou Y, Wang DW. SARS-CoV-2: a potential novel etiology of fulminant myocarditis. Herz. (2020) 45:230–2. doi: 10.1007/s00059-020-04909-z
11. Cooper LT, Baughman KL, Feldman AM, Frustaci A, Jessup M, Kuhl U, et al. The role of endomyocardial biopsy in the management of cardiovascular disease. J Am Coll Cardiol. (2007) 50:1914–31. doi: 10.1016/j.jacc.2007.09.008
12. Kontakou PM, Kostopoulos VS, Tryfou ES, Giannaris VD, Rodis IE, Olympios A, et al. Global longitudinal strain and cardiac events in patients with immune checkpoint inhibitor-related myocarditis. J Am Coll Cardiol. (2018) 259:116–21. doi: 10.1016/j.jcc.2018.01.058
13. Han J, Mou Y, Yan D, Zhang Y-T, Jiang T-A, Zhang Y-Y, et al. Transient immune checkpoint inhibitor-related myocarditis. J Am Coll Cardiol. (2020) 75:467–78. doi: 10.1016/j.jacc.2019.11.049
29. Manganaro R, Harms HJ, Aalen JM, Baron T, Smiseth OA, Flachskampf FA. Myocardial efficiency. JACC: Cardiovasc Imaging. (2019) 13:1564–76. doi: 10.1016/j.jcmg.2019.08.030

30. El Mahdoui M, van der Bijl P, Abou R, Ajmone Marsan N, Delgado V, Bax JJ. Global left ventricular myocardial work efficiency in healthy individuals and patients with cardiovascular disease. J Am Soc Echocardiogr. (2019) 32:1120–7. doi: 10.1016/j.echo.2019.05.002

31. Bouali Y, Donal E, Gallard A, Laurin C, Hubert A, Bidault A, et al. Prognostic usefulness of myocardial work in patients with heart failure and reduced ejection fraction treated by sacubitril/valsartan. Am J Cardiol. (2020) 125:1856–62. doi: 10.1016/j.amjcard.2020.03.031

Abu R, Leung M, Khidir MJH, Wolterbeek R, Schalij MJ, Ajmone Marsan N, et al. Influence of aging on level and layer-specific left ventricular longitudinal strain in subjects without structural heart disease. Am J Cardiol. (2017) 120:2655–62. doi: 10.1016/j.amjcard.2017.08.027

32. Liu J-H, Chen Y, Yuan M, Zhen Z, Chan CW-S, Lam KS-L, et al. Incremental prognostic value of global longitudinal strain in patients with type 2 diabetes mellitus. Cardiovasc Diabetol. (2015) 14:22. doi: 10.1186/s1293-016-0335-3

33. Wierzbowska-Drabik K, Trzos E, Kurpesa M, Rechciński T, Miłkowski D, Cieślak-Guerra U, et al. Diabetes as an independent predictor of left ventricular longitudinal strain reduction at rest and during dobutamine stress test in patients with significant coronary artery disease. Eur Heart J Cardiovasc Imaging. (2018) 19:1276–86. doi: 10.1093/ehjci/exs315

34. Vrettos A, Dawson D, Grigoratos C, Nihoyannopoulos P. Correlation between global longitudinal peak systolic strain and coronary artery disease severity as assessed by the angiographically derived SYNTAX score. Echo Res Pract. (2016) 3:32–9. doi: 10.1533/ERP-16-0005

35. Liu K, Negishi K, Ho S, Russell EA, Cranney G, Ooi SY. Detection of obstructive coronary artery disease using peak systolic global longitudinal strain derived by two-dimensional speckle-tracking: a systematic review and meta-analysis. J Am Soc Echocardiogr. (2019) 22:724–35.e4. doi: 10.1016/j.echo.2016.03.002

36. Smiseth OA, Torp H, Opdahl A, Haugaa KH, Urheim S. Myocardial strain imaging: how useful is it in clinical decision making? Eur Heart J. (2016) 37:1196–207. doi: 10.1093/eurheartj/ehv529

37. Thavendiranathan P, Poulin F, Lim K-D, Plana JC, Woo A, Marwick TH. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy. J Am Coll Cardiol. (2014) 63:2751–68. doi: 10.1016/j.jacc.2014.01.073

38. Stokke TM, Hasselberg NE, Smedsrud MK, Sarvari SI, Haugaa KH, Smiseth OA, et al. Geometry as a confounder when assessing ventricular systolic function. J Am Coll Cardiol. (2017) 70:942–54. doi: 10.1016/j.jacc.2016.06.046

39. Honce R, Schultz-Cherry S. Impact of obesity on influenza A virus pathogenesis, immune response, and evolution. Front Immunol. (2019) 10:1071. doi: 10.3389/fimmu.2019.01071

40. Estabragh ZR, Mamas MA. The cardiovascular manifestations of influenza: A systematic review. Int J Cardiol. (2013) 167:2397–403. doi: 10.1016/j.ijcard.2013.01.074

41. Cummings MJ, Baldwin MR, Abrams D, Jacobson BD, Balough EM, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet. (2020) 395:1763–70. doi: 10.1016/S0140-6736(20)31189-2

42. Li Y, Li H, Zhu S, Xie Y, Hou J, He L, et al. Prognostic value of right ventricular longitudinal strain in patients with COVID-19. JACC Cardiovasc Imaging. (2020) 13:2287–99. doi: 10.1016/j.jcmg.2020.04.014

43. Argulian E, Sud K, Vogel B, Bohra C, Garg VP, Talebi S, et al. Right ventricular dilation in hospitalized patients with COVID-19 infection. JACC Cardiovasc Imaging. (2020) 13:2459–61. doi: 10.1016/j.jcmg.2020.05.010

44. Ardi D, Siddiqi HK, Lang J, Naufal V, Morrow DA, Bohula EA. COVID-19 for the cardiologist: a current review of the virology, clinical epidemiology, cardiac and other clinical manifestations and potential therapeutic strategies. JACC Basic Trans Sci. (2020) 5:518–36. doi: 10.1016/j.jatbs.2020.04.002

45. Buja LM, Wolf DA, Zhao B, Akkanti B, McDonald M, Lelenwa L, et al. The emerging spectrum of cardiopulmonary pathology of the coronavirus disease 2019 (COVID-19): report of 3 autopsies from Houston, Texas, and review of autopsy findings from other United States cities. Cardiovasc Pathol. (2020) 48:107233. doi: 10.1016/j.carpath.2020.107233

46. The GBD 2015 Obesity Collaborators. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med. (2017) 377:13–27. doi: 10.1056/NEJMoa1614362

47. Kass DA, Duggal P, Cingolani O. Obesity could shift severe COVID-19 disease to younger ages. Lancet. (2020) 395:1544–5. doi: 10.1016/S0140-6736(20)31024-2

48. Pathan N, Hemingway GA, Alizadeh AA, Stephens AC, Boldrick JC, Orgui EE, et al. Role of interleukin 6 in myocardial dysfunction of meningococcal septic shock. Lancet. (2004) 363:203–9. doi: 10.1016/S0140-6736(03)15326-3
50. Johnson DE, O’Keefe RA, Grandis JR. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. *Nat Rev Clin Oncol.* (2018) 15:234–8. doi: 10.1038/nrclinonc.2018.8

51. Liu B, Li M, Zhou Z, Guan X, Xiang Y. Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? *J Autoimmun.* (2020) 111:102452. doi: 10.1016/j.jaut.2020.102452

52. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet.* (2020) 395:497–506. doi: 10.1016/S0140-6736(20)30183-5

53. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet.* (2020) 395:507–13. doi: 10.1016/S0140-6736(20)30211-7

54. Gao Y, Li T, Han M, Li X, Wu D, Xu Y, et al. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19. *J Med Virol.* (2020) 92:791–6. doi: 10.1002/jmv.25770

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Copyright © 2021 Minhas, Gilotra, Goerlich, Metkus, Garibaldi, Sharma, Bavaro, Phillip, Michos and Hays. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.**